Evidence-based recommendations on daclizumab (Zinbryta) for relapsing–remitting multiple sclerosis in adults.

The European Medicines Agency (EMA) has now restricted the use of daclizumab to patients whose disease has responded inadequately to at least 2 disease modifying therapies (DMTs) and cannot be treated with any other DMTs (see the EMA website for further details). This means that part of the population in whom daclizumab is currently recommended in NICE technology appraisal guidance 441 is outside the revised licensed indication of the drug. NICE is currently considering the appropriate next steps for NICE technology appraisal guidance 441. Please note that daclizumab can only be used within its new marketing authorisation.

Guidance development process

How we develop NICE technology appraisal guidance

Next review: April 2020

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)